What does the gut have to do with the heart in scleroderma? Quite a lot, as it turns out. In this episode, we talk with Dr. Zsuzsanna McMahan about new findings from the GENISOS cohort exploring the relationship between gastrointestinal and cardiac manifestations in systemic sclerosis, including the striking timing and strength of these associations and what they might reveal about shared disease mechanisms. Then we shift gears to the realities of academic medicine: Dr. McMahan shares lessons from moving from Johns Hopkins back to UT Houston, rebuilding clinical and research programs, forging new collaborations, and, perhaps most importantly, deciding what to say yes to and what to leave on the table

The Gut–Heart Axis in Systemic Sclerosis: Evidence From a Large Prospective Early Disease Cohort

In this episode, we speak with Dr. Pamela Weiss, pediatric rheumatologist, epidemiologist, and physician-scientist at Children's Hospital of Philadelphia, about axial juvenile spondyloarthritis (axJSpA). Dr. Weiss discusses her study examining MRI findings in children and young adults receiving TNF inhibitors, including changes in sacroiliac joint inflammation, the relationship between imaging and patient-reported outcomes, and implications for clinical care and future research. She also shares her career journey, the mentors who shaped her path, and advice for the next generation of pediatric physician-scientists.

Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease

In this episode, we speak with Dr. Ellen Romich about her post hoc analysis of the RITAZAREM trial, exploring factors associated with relapse in ANCA-associated vasculitis. She discusses the study design, key findings—including the roles of rituximab, azathioprine, CD19 positivity, ANCA status, and immune reconstitution—and the clinical implications and limitations of the work. Dr. Romich also shares her path into rheumatology, how she became involved in the analysis, and what questions she hopes to tackle next.

Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab